Mònica Aparici, Amadeu Gavaldà, Israel Ramos, Carla Carcasona, Raquel Otal, Joan Antoni Fernández-Blanco, Jose Luís Montero, Vicente Marco García, Rosa López, Jorge De Alba, Christopher Doe, Carlos Puig, Dolors Vilella, Montserrat Miralpeix
Abediterol is a novel long-acting β2-adrenoceptor agonist (LABA) currently in development for once-daily combination maintenance therapy of asthma and COPD. This study investigated the preclinical profile of abediterol in terms of affinity, potency, selectivity, duration of action and cardiac effects in comparison to the marketed once-daily LABAs indacaterol, olodaterol and vilanterol. Abediterol was the compound with the highest in vitro potency for dog, guinea pig and human β2-adrenoceptors. In electrical field stimulated guinea pig trachea, abediterol demonstrated 5-, 44- and 77-fold greater potency than olodaterol, indacaterol and vilanterol, respectively...
January 5, 2016: European Journal of Pharmacology